Abstract
The prominent immune checkpoint molecule, programmed cell death ligand-1 (PD-L1), is the object of increasing attention. Here, we report a meta-analysis investigating the safety and efficacy of durvalumab (MEDI4736), an inhibitor of PD-L1, in various solid tumors. A systematic search of PubMed, Embase, and related articles was performed. Safety data were analyzed using Comprehensive Meta-Analysis software program version 2. Ultimately, 17 studies with 1,529 patients were included in our analysis. The major adverse events associated with durvalumab were pruritus and fatigue, while pruritus, increased alanine transaminase, and increased aspartate aminotransferase were common among patients treated with a combination of durvalumab and tremelimumab. Higher PD-L1 expression was associated with a superior objective response rate. Durvalumab is safe in patients with many solid cancers and, in combination with tremelimumab, it has a tolerable safety profile and is associated with improved prognosis. PD-L1 expression is a biomarker of the efficacy of durvalumab.
Citations
Jul 6, 2019·Expert Opinion on Biological Therapy·Juliana Alvarez-Argote, Constantin A Dasanu
Mar 14, 2020·Journal of Immunotherapy·Jiabei HeYu Tang
Nov 9, 2019·Medicine·Wei-Xun ChenZe-Yang Ding
Jul 10, 2020·Thoracic Cancer·Peng SongLi Zhang
Apr 27, 2019·Cancers·Shin-Yi LiuYu-Jen Chen
Nov 12, 2020·Pharmaceuticals·Nicola J NasserAbed Agbarya
Jan 19, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Danique GiesenMartin Pool
Nov 20, 2020·BMJ Case Reports·Shivangi GuptaDavid Prentice
Mar 2, 2021·Expert Opinion on Investigational Drugs·Alessandro RizzoGiovanni Brandi
Mar 12, 2021·Frontiers in Immunology·Mahdi Abdoli ShadbadBehzad Baradaran
Jul 4, 2020·Anti-cancer Agents in Medicinal Chemistry·Navgeet KaurRakesh K Sindhu
May 25, 2021·Nanomedicine·Jeaneen Venkatas, Moganavelli Singh
Jul 1, 2021·Immunotherapy·Nikolaos CharalampakisDimitrios Schizas
Nov 20, 2021·International Journal of Hematology·Grzegorz S NowakowskiJavier Munoz